• Royalty Pharma plc recently reported first-quarter 2026 results showing revenue of US$631 million and net income of US$295 million, both higher than a year earlier, alongside continued share repurchases under its existing buyback program.
• Beyond the headline numbers, the company highlighted double-digit growth in recurring royalty receipts, increased its dividend, and committed over US$1.25 billion to new royalty and R&D funding deals, underscoring its role as a large-scale financier of biopharma innovation.
• We’ll now examine how this accelerated capital deployment into new royalty deals could influence Royalty Pharma’s pre-existing investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Royalty Pharma Investment Narrative Recap

To own Royalty Pharma, you have to believe in its role as a repeat buyer of drug royalties that turns a diverse stream of therapies into relatively stable cash flows. The latest quarter’s higher revenue and net income support that view, but do not remove key near term swing factors, such as the Alyftrek royalty dispute and the risk that competition for new deals and policy pressure on drug prices could weigh on future economics.

The most relevant recent development is Royalty Pharma’s completion of its large share buyback program, retiring about 8.79% of its shares for roughly US$1,277.27 million. Combined with the growing dividend and US$1.25 billion deployed into new royalties and R&D funding, this links capital returns directly to the core catalyst of reinvesting cash receipts into fresh deals, at a time when rising competition and policy uncertainty could challenge returns on those investments.

Yet even with rising royalties and active capital deployment, investors should still watch how concentrated cash flows and the Alyftrek dispute could...

Royalty Pharma's narrative projects $4.0 billion revenue and $922.7 million earnings by 2028. This requires 20.0% yearly revenue growth and an earnings decrease of about $77 million from $1.0 billion today.

Uncover how Royalty Pharma's forecasts yield a $51.56 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were assuming about US$3.9 billion of revenue and US$1.2 billion of earnings by 2029, but Q1’s solid results may challenge their concerns about drug pricing pressure and slower deal economics, so it is worth exploring how far your own expectations sit between those pessimistic scenarios and more optimistic views.

Explore 5 other fair value estimates on Royalty Pharma - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Royalty Pharma research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Royalty Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Royalty Pharma's overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.